Entasis Therapeutics Holdings Inc. announced the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacterbaumannii infections, including carbapenem and multidrug resistant strains. In cooperation with the FDA, expanded access, also referred to as compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. In this circumstance, Entasis Therapeutics can provide a requesting physician with pre-approval access to SUL-DUR for the treatment of the physician’s patient if specific conditions are met and there is adequate availability of drug supply. About SUL-DUR: SUL-DUR is an intravenous, or IV, investigational drug that is a combination of sulbactam, an IV ß-lactam antibiotic, and durlobactam, a novel broad-spectrum IV ß-lactamase inhibitor, or BLI, that the company is developing for the treatment of infections caused by Acinetobacter baumannii, including carbapenem-resistant strains. The company initiated ATTACK, single Phase?3 registration trial in April 2019. ATTACK is a global Phase 3 registration trial that is actively enrolling patients at sites in 17 countries including China.